John Paulson Madrigal Pharmaceuticals, Inc. Transaction History

Paulson & Co. Inc.

$1.92 Billion
Q2 2025

A detailed history of John Paulson (Paulson & Co. Inc.) transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Paulson & Co. Inc. holds 2,089,523 shares of MDGL stock, worth $903 Million. This represents 32.86% of its overall portfolio holdings.

Number of Shares

2,089,523

Previous 2,099,523 0.48%

Holding current value

$903 Million

Previous $695 Million 9.07%

% of portfolio

32.86%

Previous 39.89%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$267.56 - $340.8 $2.68 Million - $3.41 Million	-10,000 Reduced 0.48%	2,089,523 $632 Million
Q1 2025 May 15, 2025	BUY	$272.79 - $355.88 $15.7 Million - $20.5 Million	57,523 Added 2.82%	2,099,523 $695 Million
Q3 2024 Nov 14, 2024	BUY	$212.22 - $292.96 $40.7 Million - $56.2 Million	192,000 Added 10.38%	2,042,000 $433 Million
Q2 2024 Aug 14, 2024	BUY	$193.33 - $291.99 $14.5 Million - $21.9 Million	75,000 Added 4.23%	1,850,000 $518 Million
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $115 Million - $190 Million	669,259 Added 60.53%	1,775,000 $474 Million
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $72.9 Million - $144 Million	605,741 Added 121.15%	1,105,741 $256 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $21.9 Million - $33.8 Million	149,800 Added 42.78%	500,000 $73 Million
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $71.4 Million - $109 Million	350,200 New	350,200 $80.9 Million

Others Institutions Holding MDGL

# of Institutions

355

Shares Held

23.2M

Call Options Held

738K

Put Options Held

473K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $7.39B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track John Paulson's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Paulson & Co. Inc., based on Form 13F filings with the SEC.

News

Stay updated on Paulson & Co. Inc. and John Paulson with notifications on news.

Account